

## Supporting Information for

Cephaloliverols A and B, two sterol-hybrid meroterpenoids from  
*Cephalotaxus oliveri*

Chun-Yu Jiang,<sup>a,b</sup> Xiao-Jie Fan,<sup>a,b</sup> De-Li Zou,<sup>a,b</sup> Zhan-Lin Li,<sup>a,b</sup> Tong-Han,<sup>c</sup> Bin Lin,<sup>d</sup>  
Hui-Ming Hua,<sup>\*a,b</sup> Da-Hong Li<sup>\*a,b</sup>

<sup>a</sup>Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education and <sup>b</sup>School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.

<sup>c</sup>Department of Pharmaceutical Engineering, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, 5 Xinfeng Road, Daqing 163319, People's Republic of China.

<sup>d</sup>School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.

\*Corresponding Author.

E-mail: lidahong0203@163.com; huimhua@163.com

## Contents

<b>General experimental procedures.</b> .....	4
<b>Plant material</b> .....	4
<b>Extraction and isolation</b> .....	4
<b>Cell culture and determination of NO</b> .....	5
<b>Electronic circular dichroism (ECD) caculation</b> .....	5
<b>Figure S1</b> The optimized conformers of the simplified structure of <b>1</b> . .....	6
<b>Figure S2</b> The optimized conformers of the simplified structure of <b>2</b> . .....	7
<b>Figure S3</b> The optimized 3D structures of <b>2</b> with predicted interproton distance between H-4 and H <sub>3</sub> -20'. .....	7
<b>Figure S4</b> The viability of RAW 264.7 cells incubated with compounds <b>1-4</b> for 24 h.8	
<b>Figure S5</b> <sup>1</sup> H NMR spectrum (600 MHz, CDCl <sub>3</sub> ) of cephaloliverol A ( <b>1</b> ).....	9
<b>Figure S6</b> Enlarged <sup>1</sup> H NMR spectrum (600 MHz, CDCl <sub>3</sub> ) of cephaloliverol A ( <b>1</b> ) .12	
<b>Figure S7</b> <sup>13</sup> C NMR spectrum (150 MHz, CDCl <sub>3</sub> ) of cephaloliverol A ( <b>1</b> ).....	13
<b>Figure S8</b> DEPT spectrum (150 MHz, CDCl <sub>3</sub> ) of cephaloliverol A ( <b>1</b> ) .....	14
<b>Figure S9</b> HSQC spectrum of cephaloliverol A ( <b>1</b> ) .....	15
<b>Figure S10</b> HMBC spectrum of cephaloliverol A ( <b>1</b> ).....	16
<b>Figure S11</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of cephaloliverol A ( <b>1</b> ) .....	17
<b>Figure S12</b> ROESY spectrum of cephaloliverol A ( <b>1</b> ).....	18
<b>Figure S13</b> UV spectrum in CH <sub>3</sub> OH of cephaloliverol A ( <b>1</b> ) .....	19
<b>Figure S14</b> IR spectrum in KBr of cephaloliverol A ( <b>1</b> ).....	20
<b>Figure S15</b> Experimental ECD spectrum in CH <sub>3</sub> OH of cephaloliverol A ( <b>1</b> ) .....	21
<b>Figure S16</b> HRESIMS of cephaloliverol A ( <b>1</b> ) .....	22
<b>Figure S17</b> <sup>1</sup> H NMR spectrum (600 MHz, CDCl <sub>3</sub> ) of cephaloliverol B ( <b>2</b> ) .....	23
<b>Figure S18</b> Enlarged <sup>1</sup> H NMR spectrum (150 MHz, CDCl <sub>3</sub> ) of cephaloliverol B ( <b>2</b> )26	
<b>Figure S19</b> <sup>13</sup> C NMR spectrum (150 MHz, CDCl <sub>3</sub> ) of cephaloliverol B ( <b>2</b> ) .....	27
<b>Figure S20</b> DEPT spectrum (150 MHz, CDCl <sub>3</sub> ) of cephaloliverol B ( <b>2</b> ) .....	28
<b>Figure S21</b> HSQC spectrum of cephaloliverol B ( <b>2</b> ) .....	29
<b>Figure S22</b> HMBC spectrum of cephaloliverol B ( <b>2</b> ) .....	30
<b>Figure S23</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of cephaloliverol B ( <b>2</b> ).....	31

<b>Figure S24</b> ROESY spectrum of cephaloliverol B (2).....	32
<b>Figure S25</b> UV spectrum in CH <sub>3</sub> OH of cephaloliverol B (2) .....	33
<b>Figure S26</b> IR spectrum in KBr of cephaloliverol B (2).....	34
<b>Figure S27</b> Experimental ECD spectrum in CH <sub>3</sub> OH of cephaloliverol B (2).....	35
<b>Figure S28</b> HRESIMS of cephaloliverol B (2) .....	36

## **General experimental procedures**

Optical rotations were recorded on Anton Par MCP 200 polarimeter. UV spectra were measured on a Shimadzu UV-2400 spectrophotometer. ECD spectrum was recorded on Bio-Logic Science MOS-450 spectropolarimeter. HRESIMS data were measured on a Bruker micro-TOFQ-Q mass spectrometer. NMR spectroscopic data were recorded on Bruker AV-600 NMR spectrometer with tetramethylsilane as an internal standard. ODS (50  $\mu$ m, YMC Co. Ltd., Kyoto, Japan), MCI gel (Mitsubishi Chemical Industries Ltd., Tokyo, Japan) and Sephadex LH-20 (Pharmacia Biotech, Uppsala, Sweden) were used for column chromatography (CC). Semi-preparative HPLC was conducted on a YMC ODS-A column (250  $\times$  10 mm I.D., 5  $\mu$ m) equipped with a LC-6AD pump and a Shimadzu SPD-20A UV-vis detector (Shimadzu Co., Ltd., Tokyo, Japan). TLC analysis was performed on silica gel plates (GF254, Qingdao Haiyang Chemical Co., Ltd., Qingdao, PR China).

### **Plant material**

The twigs and leaves of *C. oliveri* were collected in October 2019 from Longhui County, Shaoyang City of Hunan Province, PR China, and authenticated by Mr. Hongqiang Zhang of Kunming GenPHYTech Co. Ltd, Kunming, PR China. A voucher specimen (No. 20191105) was deposited at School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, PR China.

### **Extraction and isolation**

The air-dried twigs and leaves of *C. oliveri* (50 kg) were extracted with 95% EtOH twice and 75% EtOH once. The crude EtOH extract was suspended in water and then partitioned with petroleum ether (PE), dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), and *n*-butanol (*n*-BuOH) successively to afford PE, CH<sub>2</sub>Cl<sub>2</sub>, and *n*-BuOH extracts, respectively. The CH<sub>2</sub>Cl<sub>2</sub> extract (70 g) was subjected to an MCI column eluted with CH<sub>3</sub>OH-H<sub>2</sub>O (30% to 100% CH<sub>3</sub>OH) to yield nine fractions F1-F9.

F5 was separated subsequently by ODS (30% to 70% CH<sub>3</sub>OH-H<sub>2</sub>O) to obtain four subfractions F5A-F5D. F5C was chromatographed over Sephadex LH-20, and then purified by semi-preparative HPLC (CH<sub>3</sub>OH-H<sub>2</sub>O 65:35, v/v; flow rate, 2.0 mL/min) to obtain **4** (3.0 mg,  $t_R$  = 49.8 min). F8 was subjected to

silica gel CC (petroleum ether–ethyl acetate 100:0–100:50, v/v) to get four subfractions F8A–F8D. F8A was purified by Sephadex LH–20 (CH<sub>3</sub>OH) to furnish **3** (5.1 mg). F8B was further separated by ODS, Sephadex LH–20 (CH<sub>3</sub>OH) CC and semi–preparative HPLC (CH<sub>3</sub>OH–H<sub>2</sub>O 91:9, v/v; flow rate, 2.0 mL/min) to yield **1** (6.0 mg,  $t_R = 77.8$  min) and **2** (6.0 mg,  $t_R = 87.4$  min).

Cephaloliverol A (**1**). white solid;  $[\alpha]_D^{20} -37$  ( $c$  0.3, CH<sub>3</sub>OH); UV (CH<sub>3</sub>OH)  $\lambda_{\max}$  (log  $\epsilon$ ): 253 (3.45), 284 (3.31), 335 (3.32) nm; ECD (CH<sub>3</sub>OH)  $\lambda_{\max}$  (log  $\epsilon$ ): 253 (+68.30), 280 (+102.10), 335 (–69.76) nm; IR (KBr)  $\nu_{\max}$ : 3383, 2958, 2871, 1714, 1635, 1600, 1467, 1340, 1328, 1271, 1176, 1018 cm<sup>–1</sup>; HRESIMS ( $m/z$ ): 769.5042 [M–H]<sup>–</sup> (calcd for C<sub>49</sub>H<sub>69</sub>O<sub>7</sub>, 769.5043).

Cephaloliverol B (**2**). white solid;  $[\alpha]_D^{20} +25$  ( $c$  0.3, CH<sub>3</sub>OH); UV (CH<sub>3</sub>OH)  $\lambda_{\max}$  (log  $\epsilon$ ): 253 (3.93), 285 (3.74), 334 (3.74) nm; ECD (CH<sub>3</sub>OH)  $\lambda_{\max}$  (log  $\epsilon$ ): 227 (+25.96), 279 (+82.60) nm; IR (KBr)  $\nu_{\max}$ : 3377, 2958, 2870, 1714, 1635, 1600, 1462, 1340, 1272, 1178, 1022 cm<sup>–1</sup>; HRESIMS ( $m/z$ ): 769.5074 [M–H]<sup>–</sup> (calcd for C<sub>49</sub>H<sub>69</sub>O<sub>7</sub>, 769.5043).

The other known metabolites isolated from this extract include sugiol, 3 $\beta$ -hydroxysugiol, hinokione, 3 $\beta$ ,12,16-trihydroxy-6,8,11,13-abietatrien, salviniol, hinokiol, 8 $\beta$ -hydroxy-9(11),13-abietadien-12-one, abieta-6,8,11,13-tetraene-3 $\beta$ ,12-diol, dehydrouomifoliol, epiloliolide, kaempferol, 3',4',5',5',7-pentamethoxyflavone, homoeriodictyol, naringenin, epicatechin, catechin, and 5,7-dihydroxychromone.


#### Cell culture and determination of NO

RAW 264.7 macrophages were cultured in Dulbecco's modified eagle medium (DMEM) (Hyclone, Logan, USA) with 10% fetal bovine serum (FBS, Gibco, Gaithersburg, USA) in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C for 48 h. Cells were treated with different concentrations of compounds (10, 20, and 40  $\mu$ M) and incubated for 1 h. After incubation, lipopolysaccharide (LPS) (1  $\mu$ g/mL) was introduced to cells. The culture medium was collected and used


for measuring NO production by NO Test Kit. And indomethacin (10  $\mu\text{M}$ ) was used as the positive drug.

### Electronic circular dichroism (ECD) calculation


The conformation of the simplified structure of **1** was used to search by Spartan 14.0 (Wavefunction Inc., Irvine, CA, USA) under MMFF force field. The low-energy conformers of them were optimized in the gas phase by semi-empirical method in Gaussian 09 program package, which were further reoptimized and analysed, using the density functional theory (DFT) at the RB31YP/6-31 G (d, p) level, resulted in no imaginary frequencies. Then the ECD spectra were calculated using TD-DFT-B3LYP/6-31 G (d, p) level in methanol solution. Finally, the calculated low-energy conformational results were Boltzmann averaged by software SpecDis1.51 to yield the depicted ECD spectra of the simplified structure of **1**. The ECD spectra of the simplified structure of **2** were calculated in the same method.




**Figure S1** The optimized conformers of the simplified structure of **1**.



**Figure S2** The optimized conformers of the simplified structure of **2**.



**Figure S3** The optimized 3D structures of **2** with predicted interproton distance between H-4 and H<sub>3</sub>-20'.



**Figure S4** The viability of RAW 264.7 cells incubated with compounds **1-4** for 24 h.



FB-36-101-2






Figure S5 <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of cephaloliverol A (1)

F8-36-101-2



F8-36-101-2



F8-36-101-2




Figure S6 Enlarged <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of cephaloliverol A (1)

F8-36-101-2






Figure S7 <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of cephaloliverol A (1)



**Figure S8** DEPT spectrum (150 MHz, CDCl<sub>3</sub>) of cephaloliverol A (**1**)



**Figure S9** HSQC spectrum of cephaloliverol A (1)






Figure S10 HMBC spectrum of cephaloliverol A (1)






**Figure S11**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of cephaloliverol A (**1**)


F8-36-101-2




**Figure S12** ROESY spectrum of cephaloliverol A (1)




**Figure S13** UV spectrum in CH<sub>3</sub>OH of cephaloliverol A (1)



**Figure S14** IR spectrum in KBr of cephaloliverol A (**1**)



**Figure S15** Experimental ECD spectrum in CH<sub>3</sub>OH of cephaloliverol A (**1**)



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
769.5042	769.5043	-0.1	-0.1	15.5	417.2	n/a	n/a	C <sub>49</sub> H <sub>69</sub> O <sub>7</sub>

**Figure S16** HRESIMS of cephaloliverol A (1)

F8-36-101-3





Figure S17 <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of cephaloliverol B (2)

F8-36-101-3





F8-36-101-3




Fig. S18-101-3




Figure S18 Enlarged <sup>1</sup>H NMR spectrum (150 MHz, CDCl<sub>3</sub>) of cephaloliverol B (2)

F8-36-101-3







Figure S19 <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of cephaloliverol B (2)




**Figure S20** DEPT spectrum (150 MHz, CDCl<sub>3</sub>) of cephaloliverol B (**2**)




**Figure S21** HSQC spectrum of cephaloliverol B (2)



**Figure S22** HMBC spectrum of cephaloliverol B (2)



**Figure S23**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of cephaloliverol B (2)



**Figure S24** ROESY spectrum of cephaloliverol B (2)









Figure S25 UV spectrum in CH<sub>3</sub>OH of cephaloliverol B (2)



**Figure S26** IR spectrum in KBr of cephaloliverol B (2)



**Figure S27** Experimental ECD spectrum in CH<sub>3</sub>OH of cephaloliverol B (2)



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
769.5074	769.5043	3.1	4.0	15.5	446.8	2.325	9.78	C <sub>49</sub> H <sub>69</sub> O <sub>7</sub>

**Figure S28** HRESIMS of cephaloliverol B (2)